Compare PHAT & NKLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PHAT | NKLR |
|---|---|---|
| Founded | 2018 | 2018 |
| Country | United States | Italy |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Metal Fabrications |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 676.3M | 623.2M |
| IPO Year | 2019 | 2025 |
| Metric | PHAT | NKLR |
|---|---|---|
| Price | $8.16 | $4.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | ★ $19.83 | $15.00 |
| AVG Volume (30 Days) | ★ 977.2K | 229.9K |
| Earning Date | 04-30-2026 | 04-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 42.72 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $175,110,000.00 | N/A |
| Revenue This Year | $93.04 | N/A |
| Revenue Next Year | $58.91 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 216.93 | N/A |
| 52 Week Low | $8.07 | $3.73 |
| 52 Week High | $18.31 | $12.43 |
| Indicator | PHAT | NKLR |
|---|---|---|
| Relative Strength Index (RSI) | 43.37 | 38.61 |
| Support Level | $8.46 | $4.06 |
| Resistance Level | $9.74 | $5.20 |
| Average True Range (ATR) | 0.48 | 0.37 |
| MACD | -0.02 | -0.09 |
| Stochastic Oscillator | 36.76 | 0.73 |
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
Terra Innovatum Global NV is a micro modular nuclear solutions company that aims to deliver reliable, low-cost, and zero-carbon power wherever energy demand is present through its first-of-a-kind reactor, SOLO. SOLO is compact yet extremely powerful, with one unit generating 1MWe of power, while designed with the strictest safety characteristics and the ability to run 24/7 without the need to refuel for 15 years. Its modular design aims to achieve maximum energy efficiency while significantly reducing the levelized cost of energy (LCOE). SOLO is built using off-the-shelf components and widely available fuel, low-enriched uranium (LEU), which de-risks its regulatory and commercial pathway.